Sepsis costs lives and billions. A Czech company is heading to market with a solution
Sepsis is a serious medical condition with a global impact. Each year, it affects nearly 50 million people worldwide and causes up to 11 million deaths. Even in developed countries, including Czechia, thousands of cases are reported annually, particularly in intensive care units. Yet diagnosis still relies largely on outdated culture-based methods that are slow and often fail. This has not only medical but also significant economic consequences — treatment costs per patient can reach tens of thousands of dollars.
For this reason, the Czech company DIANA Biotechnologies is developing a new ultrasensitive PCR-based method that could fundamentally change the way sepsis is diagnosed. Initial clinical results show significantly higher sensitivity compared to existing solutions and strong potential for broad routine use. “If we succeed, a multi-billion-dollar market could open up,” says company founder Martin Dienstbier in an interview with Roklen24.
He wanted to be an independent scientist — nobody would hire him
This Slovak conquered Oxford anyway and built a billion-dollar startup
Can Europe take the lead on biotech?
With uncertainty across the global financial markets and research community, is it Europe’s time to take the lead on biotech?